Angiotensin II type I receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival

British Journal of Cancer

Volumn 94, Issue 4, 2006, Pages 552-560

  Ino, K ^a   Shibata, K ^a   Kajiyama, H ^a   Yamamoto, E ^a   Nagasaka, T ^a   Nawa, A ^a   Nomura, S ^a   Kikkawa, F ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Angiotensin II; AT1 receptor; Ovarian cancer; Prognosis; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOTENSIN RECEPTOR; CD34 ANTIGEN; CYCLINE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL;

DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; SURVIVAL ANALYSIS;

EID: 33344460242     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602961     Document Type: Article

References (43)

1. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B, Sotelo J (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92: 1247-1252
2. Bamberger ES, Perrett CW (2002) Angiogenesis in epithelian ovarian cancer. Mol Pathol 55: 348-359
3. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: 532-537
4. Chua CC, Hamdy RC, Chua BH (1998) Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1401: 187-194
5. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75
6. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1998) Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83: 2528-2533
7. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K (2001) Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200
8. Fujimura H, Ino K, Nagasaka T, Nakashima N, Nakazato H, Kikkawa F, Mizutani S (2000) Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression. Oncology 58: 342-352
9. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294: 441-447
10. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33-41
11. Ino K, Uehara C, Kikkawa F, Kajiyama H, Shibata K, Suzuki T, Khin EE, Ito M, Takeuchi M, Itakura A, Mizutani S (2003) Enhancement of aminopeptidase A expression during angiotensin II-induced choriocarcinoma cell proliferation through AT1 receptor involving protein kinase C- and mitogen-activated protein kinase-dependent signaling pathway. J Clin Endocrinol Metab 88: 3973-3982
12. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, Ho MM, Payne JG, Vinson GP (1997) Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 75: 1279-1283
13. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287
14. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP, Janzer RC, Corvol P, Gasc JM (2004) Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90: 1059-1068
15. Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T, Ino K, Nomura S, Mizutani S (2004) Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 190: 1258-1263
16. Le Noble FA, Schreurs NH, van Straaten HW, Slaaf DW, Smits JF, Rogg H, Struijker-Boudier HA (1993) Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 264: R460-465
17. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863
18. Marsigliante S, Resta L, Muscella A, Vinson GP, Marzullo A, Storelli C (1996) AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett 110: 19-27
19. McGuire Jr WP, Markman M (2003) Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89(Suppl 3): S3-S8
20. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179
21. Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S (2002) Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 173: 315-323
22. Nakopoulou L, Janinis J, Panagos G, Comin G, Davaris P (1993) The immunohistochemical expression of proliferating cell nuclear antigen (PCNA/cyclin) in malignant and benign epithelial ovarian neoplasms and correlation with prognosis. Eur J Cancer 29A: 1599-1601
23. Nielsen AH, Hagemann A, Poulsen K (1995) The tissue renin-angiotensin system in the female reproductive tissues: a review. Adv Exp Med Biol 377: 253-268
24. Obermair A, Wasicky R, Kaider A, Preyer O, Losch A, Leodolter S, Kolbl H (1999) Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 138: 175-182
25. Ogawa S, Kaku T, Kobayashi H, Hirakawa T, Ohishi Y, Kinukawa N, Nakano H (2002) Prognostic significance of micro vessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176: 111-118
26. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9: 1138-1150
27. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M (1999) Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 10: 245-255
28. Richard DE, Vouret-Craviari V, Pouyssegur J (2001) Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 20: 1556-1562
29. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85: 1396-1399
30. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196-203
31. Shiraishi S, Nakagawa K, Kinukawa N, Nakano H, Sueishi K (1996) Immunohistochemical localization of vascular endothelial growth factor in the human placenta. Placenta 17: 111-121
32. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11: 2686-2694
33. Suganuma T, Ino K, Shibata K, Nomura S, Kajiyama H, Kikkawa F, Tsuruoka N, Mizutani S (2004) Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab Invest 84: 639-648
34. Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158: 1633-1637
35. Tamarat R, Silvestre JS, Durie M, Levy BI (2002) Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 82: 747-756
36. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE, Price P (1995) Proliferating cell nuclear antigen (PCNA) immunostaining - a prognostic factor in ovarian cancer? Br J Cancer 71: 357-362
37. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T (1996) Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77: 1101-1106
38. Ueda M, Terai Y, Kumagai K, Ueki K, Okamoto Y, Ueki M (1999) Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma. Hum Pathol 30: 1389-1394
39. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2: 1139-1147
40. Watanabe Y, Shibata K, Kikkawa F, Kajiyama H, Ino K, Hattori A, Tsujimoto M, Mizutani S (2003) Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin-angiotensin system. Clin Cancer Res 9: 6497-6503
41. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887
42. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227
43. Yoshiji H, Kuriyama S, Kawata M, Yoshiji J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078